An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Zegalogue

Chemical Namedasiglucagon
Dosage FormInjection (subcutaneous; 0.6 mg/0.6 mL)
Drug ClassMiscellaneous
SystemBlood
CompanyZealand Pharma A/S
Approval Year2021

Indication

  • Indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.
Last updated on 3/26/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zegalogue (dasiglucagon) Prescribing Information2021Zealand Pharma A/S, 2860 Søborg, Denmark
Document TitleYearSource
A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in rescue treatment of hypoglycemia in subjects with Type 1 Diabetes Mellitus compared to placebo and with reference to GlucaGen.2020Zealand Pharma
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with Type 1 Diabetes Mellitus (T1DM) compared to placebo.2020Zealand Pharma
Phase 3, randomized, double-blind, placebo/active-controlled, parallel-arm trial to assess efficacy, safety, and pharmacokinetics of dasiglucagon relative to placebo/GlucaGen® as rescue therapy for severe hypoglycemia in children with T1DM treated with insulin.2020Zealand Pharma